Skip to main content
. 2022 Mar 28;71(11):2631–2643. doi: 10.1007/s00262-022-03185-6

Fig. 3.

Fig. 3

Progression-free survival (PFS) and overall survival (OS) according to the treatment response to lenvatinib plus pembrolizumab. Kaplan–Meier curves of a PFS according to RECIST v1.1; b OS stratified by treatment response. CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease